Viridian Therapeutics price target lowered to $35 from $44 at RBC Capital

RBC Capital lowered the firm’s price target on Viridian Therapeutics to $35 from $44 but keeps an Outperform rating on the shares. The analyst cites the company’s leadership transition while introducing more cautious program probabilities to afford the management team greater execution cushion to capture value, even though it also notes that its program timelines are “importantly intact”.